Drug Approval | October 18, 2021
U.S. FDA approves Roche’s Tecentriq as adjuvant treatment for small cell lung cancer
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
The trial met the primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenib
The interim analysis showed that the MVC-COV1901 vaccine has a good safety profile and elicits promising neutralising antibody titres
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
The consortium envisages carrying out surveillance of important bacterial, viral and parasitic infections of zoonotic as well as transboundary pathogens
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
The survey revealed that improving customer experience (CX) and operational efficiencies are top priorities, which healthcare organizations aim to attain by deploying digital health solutions
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
Subscribe To Our Newsletter & Stay Updated
